NEW YORK--(BUSINESS WIRE)--Nov. 18, 2005--Ogan Gurel, MD MPhil, CEO of Duravest, Inc., (OTC BB:DUVT, XETRA:DUV) capped breakfast and luncheon meetings yesterday with members of the Wall Street financial community with a dinner meeting with the Financial Investment Analysts (FIA) at which he gave a presentation of the company’s history and present and future prospects and answered questions from the assembled groups. The meetings were prompted by the intense interest in Duravest since it announced (October 28, 2005) the successful preliminary results of its subsidiary Estracure’s Phase II “proof-of-concept” clinical trial with 17-beta-estradiol. The results were first revealed at the recent Canadian Cardiovascular Congress by Dr Jean-Francois Tanguay, MD, CPSQ, FRCP of the Montreal Heart Institute and Chief Scientific Officer of Estracure.